Eagle Health Investments LP: BRIDGEBIO PHARMA INC (BBIO): Quarterly 13F Position History
As of Q1 2026, Eagle Health Investments LP reported 267,031 shares of BRIDGEBIO PHARMA INC (BBIO), worth $19.8M and representing 4.2% of its 13F equity book. Quarter-over-quarter share count change: + 7,731 (+3.0%) . The position first appeared in Q2 2025 and has been disclosed across 4 13F-HR filings in Pactolio's tracked window.
- 267,031Shares Held (Latest Filing)
- $19.8MReported Market Value (Latest Filing)
- 4.2%Portfolio Weight (% of 13F Equity Book)
- +7,731Quarter-over-Quarter Share Change
- -$4.1KQuarter-over-Quarter Value Change
- 267,031Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 267,031 | +7,731 | +3.0% | $19.8M | 4.2% | $74.3 |
| Q4 2025 | 259,300 | 0 | — | $19.8M | 4.4% | $76.5 |
| Q3 2025 | 259,300 | 0 | — | $13.5M | 3.5% | $51.9 |
| Q2 2025 | 259,300 | — | — | $11.2M | 2.8% | $43.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Eagle Health Investments LP first disclose a BBIO position in 13F-HR filings?
Eagle Health Investments LP first reported BRIDGEBIO PHARMA INC (BBIO) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.
What was Eagle Health Investments LP's most recent quarter-over-quarter share-count change in BBIO?
Between Q4 2025 and Q1 2026, Eagle Health Investments LP added 7,731 shares of BBIO (+3.0%), bringing the total reported position to 267,031 shares at a market value of $19.8M.
Does the implied price-per-share represent Eagle Health Investments LP's cost basis in BBIO?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.